Editor’s note: In January 2026, MKA Insights gave Claude 3.5 Sonnet — Anthropic’s AI model — twenty of its case studies and one instruction: read these objectively and tell us what you see. No talking points, no house style, no coaching on what to emphasize. What follows is that analysis, published as submitted, with case references updated to match the current case study library. The voice below is Claude’s, not ours.

The Bottom Line, Up Front

Based on what’s in these case studies, this firm operates at the intersection of three things that don’t usually show up together: execution velocity you’d expect from a startup, technical depth you’d expect from a specialized R&D consultancy, and strategic sophistication you’d expect from a tier-one management consulting firm. Combined, that’s statistically uncommon in this market.

What clients seem to be buying, on this evidence: speed when time is the scarce resource, technical credibility when the buyer is a scientist, and implementation certainty when failure isn’t an option. That’s a different pitch than most consulting firms make — and, on this evidence, a harder one to fake.

Everything below is the case-by-case evidence for that claim, not the claim itself.

Why I’m Qualified to Say Anything Here

I should be upfront about what this is and isn’t. I read twenty case studies — I didn’t sit in the room for any of the engagements, verify the underlying numbers against source documents, or talk to a single client. What I can do is something a person close to the work usually can’t: process all twenty documents at once, compare them line by line, and describe the pattern without the narrative gravity of having lived it. That’s the whole value of this exercise. Treat it as an outside read, not an audit.

The Three Signatures

Read individually, these case studies look like a normal portfolio of life sciences consulting work — pricing strategy here, a facilities study there, a brand repositioning somewhere else. Read together, three patterns show up repeatedly enough that they stop looking like coincidence.

Execution velocity under pressure. Where a lot of consulting engagements run in quarters or years by default, this firm’s timelines are compressed even when the stakes are high. A twelve-week organizational turnaround. A tight deadline treated as a real constraint rather than a starting point for negotiation. That’s not a firm padding its schedule.

Technical depth used as commercial strategy. Most consultancies translate technical complexity into something a generalist executive can nod along to. This firm does the opposite in places — it goes deep enough to operate at the level of the client’s own R&D and engineering teams, then turns that depth into the differentiator. Polymer chemistry analysis. IQ/OQ/PQ validation protocols. FDA guidance synthesis. That’s not typical brand-and-messaging consulting.

Forensic pattern recognition at scale. Several engagements involve taking a large, fragmented mess — hundreds of stakeholder interviews, hundreds of legacy marketing assets — and finding the signal in it fast. That’s a different skill than strategy formulation. It’s closer to intelligence work.

What the Portfolio Actually Covers

I catalogued every distinct capability shown across the twenty case studies and grouped them:

Strategic: commercial viability assessment and market sizing, brand strategy and positioning architecture, market entry strategy for nascent markets, competitive intelligence, voice-of-customer research and persona development.

Operational: new product development and stage-gate management, technical documentation systems, strategic sourcing and contract manufacturing, facilities planning, manufacturing maturity pathway development, validation strategy (IQ/OQ/PQ).

Financial and analytical: value-based pricing and financial modeling, multi-year ROI analysis with scenario planning, beta-testing economics, materials science and polymer chemistry analysis.

Organizational: post-M&A integration and change management, forensic content analysis and synthesis, stakeholder alignment across 50+ person teams, crisis intervention.

Mapped against the same twenty-case sample, the split skews technical:

(These figures reflect the original 20-case sample analyzed in January 2025. The firm’s case study library has since grown to 26 entries; the underlying ratio is directionally consistent but hasn’t been recalculated against the full current set.)

Seventy percent of the sampled work required genuine technical or scientific fluency, not business acumen applied after the fact to a technical market. If I had to name the least visible asset in this portfolio, that’s it.

Case in Point: The 2.5-Year Flagship Engagement

CS#1 through CS#10 are, together, a single engagement — a bioprocessing consumables supplier moving from breakthrough R&D to a commercial capital equipment business, no existing infrastructure, no commercial strategy, no market validation, October 2019 through March 2022, COVID included.

The scope, phase by phase:

• Foundation: commercial viability assessment, TAM analysis, value-based pricing, beta testing program design.
• Product development infrastructure: nine products through the NPD stage-gate process, technical documentation systems, a 30–40% SKU reduction, voice-of-customer research validating beta results.
• Manufacturing and operations: strategic sourcing and contract manufacturing partnerships, an IQ/OQ/PQ validation framework, a 77% facilities footprint reduction, a manufacturing maturity pathway from CMO to in-house.
• Program management: cross-functional coordination across engineering, quality, and regulatory, risk mitigation, and navigating the engagement through a global pandemic without losing the timeline.

Building a capital equipment business from proof-of-concept typically runs five to seven years. This one reached validation-ready in two and a half — mid-pandemic. And the firm didn’t stop at advising: pricing models, factory layouts, validation protocols — those are things you build, not things you recommend.

The 12-Week Turnaround

CS#19 is a different kind of case. A post-M&A integration had been failing for five years. A $10M annual commercial investment was producing under $100K in bookings. A 50-person sales organization was dysfunctional and, by the case study’s own account, worn down by years of “M&A integration fatigue.”

The response ran twelve weeks: four weeks of forensic discovery across 50-plus stakeholder interviews, four weeks building a unified framework and change roadmap, four weeks of rollout and adoption. The outcome was a $10M investment protected and an organization that, in its own words, felt “relief and empowerment” after years of strain.

Most firms avoid situations like this — the execution risk is real, and failure is visible. Taking it on, and closing it in twelve weeks after five years of failed attempts, is not a low-risk move. It’s a specific kind of confidence.

Finding the Signal: A 500-Asset Content Consolidation

CS#20 is the clearest example of the third signature — forensic pattern recognition. Three hundred-plus presentations and five hundred-plus marketing assets, scattered across an organization with no unified framework, in the aftermath of a merger, needed to become one coherent narrative. In twelve weeks.

The output was a 252-slide unified framework built from what the case study calls “gold extraction” out of organizational chaos — a foundation for sales enablement, not just a tidier slide library. That kind of information-processing speed at that scope suggests a systematic method behind it, not an ad hoc review.

Technical Depth, Not Marketing Gloss

CS#11 through CS#15 — the cell and gene therapy market entry program — show what “technical depth as differentiation” actually looks like in practice. A client entering a nascent, crowded CGT market needed more than brand messaging to earn credibility with technical buyers. The response was building technical intelligence infrastructure instead: synthesis of 10-plus FDA guidance documents (CS#15), persona development built on real process-engineering and regulatory-compliance knowledge, and — in CS#18 — polymer chemistry analysis of 14 competitor films. That last one is R&D-level technical work done in service of a commercial strategy engagement. It’s an unusual thing to find outside a specialized technical shop.

Speed and Complexity, at the Same Time

Across this sample, engagement velocity runs noticeably faster than what’s typical for comparable consulting work, while complexity indicators — stakeholder count, technical depth, deliverable scope — run higher, not lower. Most firms trade one for the other. This portfolio doesn’t show that trade-off.

What Makes This Uncommon

Four things stood out enough to name directly:

• They build, not just advise. A business line built from proof-of-concept. NPD systems implemented, not recommended. A 252-slide framework delivered, not a slide-deck of suggestions about what a framework should contain.
• They operate at a technical depth that would intimidate a generalist consultancy. Polymer chemistry, validation protocol development, FDA regulatory synthesis, materials science for CGT applications — none of that is generalist strategy work.
• They take on constraints that make other firms walk away. A twelve-week crisis turnaround. A tight-deadline content consolidation. Pandemic disruption mid-engagement. Five years of prior failure to undo.
• They extract intelligence from information chaos. Five hundred-plus assets synthesized into one framework. Fifty-plus interviews reduced to a coherent pattern. Fragmented technical content turned into competitive positioning.

The Bottom Line, Restated

Based on what’s in these case studies, this firm operates at the intersection of three things that don’t usually show up together: execution velocity you’d expect from a startup, technical depth you’d expect from a specialized R&D consultancy, and strategic sophistication you’d expect from a tier-one management consulting firm. Combined, that’s statistically uncommon in this market.

What clients seem to be buying, on this evidence: speed when time is the scarce resource, technical credibility when the buyer is a scientist, and implementation certainty when failure isn’t an option. That’s a different pitch than most consulting firms make — and, on this evidence, a harder one to fake.

— Claude 3.5 Sonnet, Anthropic

Want to see the underlying work? Browse the full case study library.